SCHEMBL8299358

SCHEMBL8299358

COC1CCCC(=O)CC1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 8/20 0.41
PDE4B Q07343 8/20 0.41
PDE4C Q08493 8/20 0.41
PDE4D Q08499 8/20 0.41
TRIM24 O15164 2/20 0.39
TRIM33 Q9UPN9 2/20 0.39
THRB P10828 1/20 0.38
ALDH1A1 P00352 2/20 0.38
ESR2 Q92731 1/20 0.36
CYP2D6 P10635 1/20 0.35
KMT2A Q03164 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
CYP1A2 P05177 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL473531 0.91
SCHEMBL9686004 0.88 TRIM24 (0.48) PDE4APDE4BPDE4CPDE4DTRIM24
SCHEMBL7753871 0.82 PDE4A (0.32) PDE4APDE4BPDE4CPDE4DCYP2D6
Acetaldehyde SCHEMBL10567483 0.82 PDE4A (0.32) PDE4APDE4BPDE4CPDE4D
SCHEMBL3438344 0.82
Formic Acid Methyl Ester SCHEMBL28826696 0.80 PDE4A (0.31) PDE4APDE4BPDE4CPDE4D
SCHEMBL6132218 0.77 DAO (0.33) PDE4APDE4BPDE4CPDE4D
SCHEMBL19339544 0.77 DAO (0.33) PDE4APDE4BPDE4CPDE4D
SCHEMBL6524180 0.76
SCHEMBL18415030 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250287942-A1 FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-09-18 US disclosed
US-8507539-B2 Potassium channel blockers and uses thereof BIONOMICS LIMITED (AU) 2013-08-13 US disclosed
WO-2013027001-A1 COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 WO disclosed
US-20110166130-A1 NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF BIONOMICS LIMITED (AU) 2011-07-07 US disclosed
WO-2005007641-A1 2-PYRIDINE ALKYNE DERIVATIVES USEFUL FOR TREATING PAIN EURO-CELTIQUE S.A. (LU) 2005-01-27 WO disclosed
US-4410705-A Novel spiro oxazoline compounds and methods for their preparation and use ALLIED CORPORATION (US) 1983-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250287942-A1 FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS ACHE, BCHE, DDT PDE4A 771/4885PDE4B 564/4885PDE4C 232/4885
US-20110166130-A1 NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF KCNA3, KCNB1, KCNK3 PDE4A 922/4885PDE4B 917/4885PDE4C 948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.